Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farshid Dayyani

Showing results (71-80 of 115) with videos related to

Pageof 12
Sort By:
Journal of Gastrointestinal Oncology|March 12, 2026
The association between adherence to elective nodal volume guidelines and reduced distant metastasis in esophageal and gastroesophageal junction cancer: a retrospective analysis of elective nodal irradiationJared Lyons, Garrett Harada, John Yeakel, et al.
Blood|February 9, 2008
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survivalFarshid Dayyani, Jianfeng Wang, Jing-Ruey J Yeh, et al.
Cancer|February 18, 2010
Cause of death in patients with lower-risk myelodysplastic syndromeFarshid Dayyani, Anthony P Conley, Sara S Strom, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)Thomas Muley, Vinzent Rolny, Ying He, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
The Oncologist|June 21, 2024
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancersBushra Shariff, Reagan M Barnett, Farshid Dayyani, et al.
The International Journal of Biological Markers|March 29, 2024
A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysisBruno Köhler, Marta Bes, Henry Lik-Yuen Chan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2021
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.
Cancers|January 21, 2022
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary ApproachMay T Cho, Sepideh Gholami, Dorina Gui, et al.
Pageof 12

Showing results (71-80 of 115) with videos related to

Sort By:
Pageof 12
Journal of Gastrointestinal Oncology|March 12, 2026
The association between adherence to elective nodal volume guidelines and reduced distant metastasis in esophageal and gastroesophageal junction cancer: a retrospective analysis of elective nodal irradiationJared Lyons, Garrett Harada, John Yeakel, et al.
Blood|February 9, 2008
Loss of TLE1 and TLE4 from the del(9q) commonly deleted region in AML cooperates with AML1-ETO to affect myeloid cell proliferation and survivalFarshid Dayyani, Jianfeng Wang, Jing-Ruey J Yeh, et al.
Cancer|February 18, 2010
Cause of death in patients with lower-risk myelodysplastic syndromeFarshid Dayyani, Anthony P Conley, Sara S Strom, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
The combination of the blood based tumor biomarkers cytokeratin 19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as a potential predictor of benefit from adjuvant chemotherapy in early stage squamous cell carcinoma of the lung (SCC)Thomas Muley, Vinzent Rolny, Ying He, et al.
BMC Cancer|September 8, 2016
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory studyFarshid Dayyani, Amado J Zurita, Graciela M Nogueras-González, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 9, 2021
Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure-safety analyses in patients with metastatic pancreatic cancerKarl Brendel, Tanios Bekaii-Saab, Patrick M Boland, et al.
The Oncologist|June 21, 2024
Circulating tumor DNA molecular analyses and real-world evidence outcomes of FGFR2 amplified gastroesophageal cancersBushra Shariff, Reagan M Barnett, Farshid Dayyani, et al.
The International Journal of Biological Markers|March 29, 2024
A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysisBruno Köhler, Marta Bes, Henry Lik-Yuen Chan, et al.
European Journal of Cancer (Oxford, England : 1990)|May 6, 2021
First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II studyZev A Wainberg, Tanios Bekaii-Saab, Patrick M Boland, et al.
Cancers|January 21, 2022
Optimizing the Diagnosis and Biomarker Testing for Patients with Intrahepatic Cholangiocarcinoma: A Multidisciplinary ApproachMay T Cho, Sepideh Gholami, Dorina Gui, et al.
Pageof 12